A double-blind block randomized clinical trial on the effect of zinc as a treatment for diarrhea in neonatal Holstein calves under natural challenge conditions

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Diarrhea is the leading cause of death in neonatal calves and contributes to major economic losses. The objective of this double-blind randomized clinical trial was to evaluate the effect of oral inorganic or organic zinc supplementation as a treatment for neonatal diarrhea in calves. Seventy nine 1 to 8 day old male Holstein calves on a California calf ranch were block randomized to one of 3 treatments within 24. h from their first onset of diarrhea. Calves received a daily dose of either a placebo composed of 80. mg of zinc-free powder, 381.54. mg of zinc methionine (Met) (equivalent to 80. mg of zinc), or 99.69. mg of zinc oxide (ZO) (equivalent to 80. mg of zinc) in 2. L of a zinc-free oral rehydration solution (ORS). Calves were treated once daily until normal fecal consistency or for a maximum of 14 days. Upon enrollment and exit, calves were weighed, and blood, feces, and liver biopsies were collected for trace mineral analysis. Fecal samples at enrollment and exit were tested for E. coli K99, Cryptosporidium spp., rotavirus and coronavirus. Pre-treatment liver zinc concentrations for the 71 calves in the placebo, zinc Met, and ZO treatment groups were 710.6 (SEM. = 147.7), 852.3 (SEM. = 129.6), and 750.7 (SEM. = 202.9). mg/kg dry weight (DW), respectively. Exit liver zinc concentrations for the calves in the placebo, zinc Met, and ZO treatment groups were 728.9 (SEM. = 182.9), 1141.0 (SEM. = 423.8), and 636.8 (SEM. = 81.5). mg/kg dry weight, respectively. Although statistically non-significant, there were clinically important findings identified for each of zinc Met and ZO treatments. Calves treated with zinc Met gained on average 40. g/day during a diarrhea episode compared to a weight loss of 67. g/day on average in the placebo-treated calves (Power 19.9%). Calves treated with ZO had 1.4 times higher hazard of clinical cure compared to calves in the placebo group (Power 5.3%). Calves that were fecal positive to cryptosporidium spp. at enrollment and treated with zinc Met had higher odds of testing negative at exit compared to placebo calves (Odds Ratio (OR). = 16.0). In contrast, calves treated with ZO tended to recover (fecal score. = 1) one day earlier compared to calves treated with a placebo (8.5 d vs. 9.7 d). The current trial identified clinically important findings that warrant further research to investigate zinc's therapeutic effect for calf diarrhea.

Original languageEnglish (US)
Pages (from-to)338-347
Number of pages10
JournalPreventive Veterinary Medicine
Volume112
Issue number3-4
DOIs
StatePublished - Nov 1 2013

Fingerprint

randomized clinical trials
Zinc Oxide
Zinc
Diarrhea
diarrhea
Holstein
Randomized Controlled Trials
zinc
calves
Placebos
zinc methionine
zinc oxide
placebos
Cryptosporidium
Therapeutics
Liver
Rehydration Solutions
Weights and Measures
Coronavirus
Rotavirus

Keywords

  • Calf
  • Cryptosporidium
  • Diarrhea
  • Zinc methionine
  • Zinc oxide

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Food Animals

Cite this

@article{350423eacc294b87a8e963745251901b,
title = "A double-blind block randomized clinical trial on the effect of zinc as a treatment for diarrhea in neonatal Holstein calves under natural challenge conditions",
abstract = "Diarrhea is the leading cause of death in neonatal calves and contributes to major economic losses. The objective of this double-blind randomized clinical trial was to evaluate the effect of oral inorganic or organic zinc supplementation as a treatment for neonatal diarrhea in calves. Seventy nine 1 to 8 day old male Holstein calves on a California calf ranch were block randomized to one of 3 treatments within 24. h from their first onset of diarrhea. Calves received a daily dose of either a placebo composed of 80. mg of zinc-free powder, 381.54. mg of zinc methionine (Met) (equivalent to 80. mg of zinc), or 99.69. mg of zinc oxide (ZO) (equivalent to 80. mg of zinc) in 2. L of a zinc-free oral rehydration solution (ORS). Calves were treated once daily until normal fecal consistency or for a maximum of 14 days. Upon enrollment and exit, calves were weighed, and blood, feces, and liver biopsies were collected for trace mineral analysis. Fecal samples at enrollment and exit were tested for E. coli K99, Cryptosporidium spp., rotavirus and coronavirus. Pre-treatment liver zinc concentrations for the 71 calves in the placebo, zinc Met, and ZO treatment groups were 710.6 (SEM. = 147.7), 852.3 (SEM. = 129.6), and 750.7 (SEM. = 202.9). mg/kg dry weight (DW), respectively. Exit liver zinc concentrations for the calves in the placebo, zinc Met, and ZO treatment groups were 728.9 (SEM. = 182.9), 1141.0 (SEM. = 423.8), and 636.8 (SEM. = 81.5). mg/kg dry weight, respectively. Although statistically non-significant, there were clinically important findings identified for each of zinc Met and ZO treatments. Calves treated with zinc Met gained on average 40. g/day during a diarrhea episode compared to a weight loss of 67. g/day on average in the placebo-treated calves (Power 19.9{\%}). Calves treated with ZO had 1.4 times higher hazard of clinical cure compared to calves in the placebo group (Power 5.3{\%}). Calves that were fecal positive to cryptosporidium spp. at enrollment and treated with zinc Met had higher odds of testing negative at exit compared to placebo calves (Odds Ratio (OR). = 16.0). In contrast, calves treated with ZO tended to recover (fecal score. = 1) one day earlier compared to calves treated with a placebo (8.5 d vs. 9.7 d). The current trial identified clinically important findings that warrant further research to investigate zinc's therapeutic effect for calf diarrhea.",
keywords = "Calf, Cryptosporidium, Diarrhea, Zinc methionine, Zinc oxide",
author = "Glover, {A. D.} and Birgit Puschner and Rossow, {Heidi A} and Lehenbauer, {Terry W} and Champagne, {J. D.} and Blanchard, {Patricia C} and Aly, {Sharif S}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.prevetmed.2013.09.001",
language = "English (US)",
volume = "112",
pages = "338--347",
journal = "Preventive Veterinary Medicine",
issn = "0167-5877",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - A double-blind block randomized clinical trial on the effect of zinc as a treatment for diarrhea in neonatal Holstein calves under natural challenge conditions

AU - Glover, A. D.

AU - Puschner, Birgit

AU - Rossow, Heidi A

AU - Lehenbauer, Terry W

AU - Champagne, J. D.

AU - Blanchard, Patricia C

AU - Aly, Sharif S

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Diarrhea is the leading cause of death in neonatal calves and contributes to major economic losses. The objective of this double-blind randomized clinical trial was to evaluate the effect of oral inorganic or organic zinc supplementation as a treatment for neonatal diarrhea in calves. Seventy nine 1 to 8 day old male Holstein calves on a California calf ranch were block randomized to one of 3 treatments within 24. h from their first onset of diarrhea. Calves received a daily dose of either a placebo composed of 80. mg of zinc-free powder, 381.54. mg of zinc methionine (Met) (equivalent to 80. mg of zinc), or 99.69. mg of zinc oxide (ZO) (equivalent to 80. mg of zinc) in 2. L of a zinc-free oral rehydration solution (ORS). Calves were treated once daily until normal fecal consistency or for a maximum of 14 days. Upon enrollment and exit, calves were weighed, and blood, feces, and liver biopsies were collected for trace mineral analysis. Fecal samples at enrollment and exit were tested for E. coli K99, Cryptosporidium spp., rotavirus and coronavirus. Pre-treatment liver zinc concentrations for the 71 calves in the placebo, zinc Met, and ZO treatment groups were 710.6 (SEM. = 147.7), 852.3 (SEM. = 129.6), and 750.7 (SEM. = 202.9). mg/kg dry weight (DW), respectively. Exit liver zinc concentrations for the calves in the placebo, zinc Met, and ZO treatment groups were 728.9 (SEM. = 182.9), 1141.0 (SEM. = 423.8), and 636.8 (SEM. = 81.5). mg/kg dry weight, respectively. Although statistically non-significant, there were clinically important findings identified for each of zinc Met and ZO treatments. Calves treated with zinc Met gained on average 40. g/day during a diarrhea episode compared to a weight loss of 67. g/day on average in the placebo-treated calves (Power 19.9%). Calves treated with ZO had 1.4 times higher hazard of clinical cure compared to calves in the placebo group (Power 5.3%). Calves that were fecal positive to cryptosporidium spp. at enrollment and treated with zinc Met had higher odds of testing negative at exit compared to placebo calves (Odds Ratio (OR). = 16.0). In contrast, calves treated with ZO tended to recover (fecal score. = 1) one day earlier compared to calves treated with a placebo (8.5 d vs. 9.7 d). The current trial identified clinically important findings that warrant further research to investigate zinc's therapeutic effect for calf diarrhea.

AB - Diarrhea is the leading cause of death in neonatal calves and contributes to major economic losses. The objective of this double-blind randomized clinical trial was to evaluate the effect of oral inorganic or organic zinc supplementation as a treatment for neonatal diarrhea in calves. Seventy nine 1 to 8 day old male Holstein calves on a California calf ranch were block randomized to one of 3 treatments within 24. h from their first onset of diarrhea. Calves received a daily dose of either a placebo composed of 80. mg of zinc-free powder, 381.54. mg of zinc methionine (Met) (equivalent to 80. mg of zinc), or 99.69. mg of zinc oxide (ZO) (equivalent to 80. mg of zinc) in 2. L of a zinc-free oral rehydration solution (ORS). Calves were treated once daily until normal fecal consistency or for a maximum of 14 days. Upon enrollment and exit, calves were weighed, and blood, feces, and liver biopsies were collected for trace mineral analysis. Fecal samples at enrollment and exit were tested for E. coli K99, Cryptosporidium spp., rotavirus and coronavirus. Pre-treatment liver zinc concentrations for the 71 calves in the placebo, zinc Met, and ZO treatment groups were 710.6 (SEM. = 147.7), 852.3 (SEM. = 129.6), and 750.7 (SEM. = 202.9). mg/kg dry weight (DW), respectively. Exit liver zinc concentrations for the calves in the placebo, zinc Met, and ZO treatment groups were 728.9 (SEM. = 182.9), 1141.0 (SEM. = 423.8), and 636.8 (SEM. = 81.5). mg/kg dry weight, respectively. Although statistically non-significant, there were clinically important findings identified for each of zinc Met and ZO treatments. Calves treated with zinc Met gained on average 40. g/day during a diarrhea episode compared to a weight loss of 67. g/day on average in the placebo-treated calves (Power 19.9%). Calves treated with ZO had 1.4 times higher hazard of clinical cure compared to calves in the placebo group (Power 5.3%). Calves that were fecal positive to cryptosporidium spp. at enrollment and treated with zinc Met had higher odds of testing negative at exit compared to placebo calves (Odds Ratio (OR). = 16.0). In contrast, calves treated with ZO tended to recover (fecal score. = 1) one day earlier compared to calves treated with a placebo (8.5 d vs. 9.7 d). The current trial identified clinically important findings that warrant further research to investigate zinc's therapeutic effect for calf diarrhea.

KW - Calf

KW - Cryptosporidium

KW - Diarrhea

KW - Zinc methionine

KW - Zinc oxide

UR - http://www.scopus.com/inward/record.url?scp=84886804068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886804068&partnerID=8YFLogxK

U2 - 10.1016/j.prevetmed.2013.09.001

DO - 10.1016/j.prevetmed.2013.09.001

M3 - Article

C2 - 24074841

AN - SCOPUS:84886804068

VL - 112

SP - 338

EP - 347

JO - Preventive Veterinary Medicine

JF - Preventive Veterinary Medicine

SN - 0167-5877

IS - 3-4

ER -